Orgenesis (ORGS) Competitors $2.58 +0.08 (+3.07%) As of 03:02 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. VRPX, XFOR, CTOR, VNRX, AADI, HOWL, IMMX, IPSC, ITRM, and OTLKShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Virpax Pharmaceuticals (VRPX), X4 Pharmaceuticals (XFOR), Citius Oncology (CTOR), VolitionRx (VNRX), Aadi Bioscience (AADI), Werewolf Therapeutics (HOWL), Immix Biopharma (IMMX), Century Therapeutics (IPSC), Iterum Therapeutics (ITRM), and Outlook Therapeutics (OTLK). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Virpax Pharmaceuticals X4 Pharmaceuticals Citius Oncology VolitionRx Aadi Bioscience Werewolf Therapeutics Immix Biopharma Century Therapeutics Iterum Therapeutics Outlook Therapeutics Orgenesis (NASDAQ:ORGS) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk. Does the MarketBeat Community prefer ORGS or VRPX? Virpax Pharmaceuticals received 2 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOrgenesisOutperform Votes1100.00% Underperform VotesNo VotesVirpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% Do analysts recommend ORGS or VRPX? Virpax Pharmaceuticals has a consensus price target of $75.00, suggesting a potential upside of 11,102.39%. Given Virpax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Virpax Pharmaceuticals is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings & valuation, ORGS or VRPX? Virpax Pharmaceuticals has lower revenue, but higher earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K18.70-$55.36MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Does the media favor ORGS or VRPX? In the previous week, Virpax Pharmaceuticals had 2 more articles in the media than Orgenesis. MarketBeat recorded 3 mentions for Virpax Pharmaceuticals and 1 mentions for Orgenesis. Virpax Pharmaceuticals' average media sentiment score of 0.00 beat Orgenesis' score of -0.71 indicating that Virpax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orgenesis 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Virpax Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, ORGS or VRPX? Orgenesis has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Do insiders & institutionals believe in ORGS or VRPX? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is ORGS or VRPX more profitable? Virpax Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% Virpax Pharmaceuticals N/A -1,554.34%-338.29% SummaryVirpax Pharmaceuticals beats Orgenesis on 9 of the 14 factors compared between the two stocks. Remove Ads Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.38M$6.73B$5.54B$7.49BDividend YieldN/A2.79%4.86%4.04%P/E RatioN/A6.9923.2518.07Price / Sales18.70198.60361.2686.83Price / CashN/A65.6738.1634.64Price / Book-0.395.926.493.99Net Income-$55.36M$142.37M$3.21B$247.18M7 Day Performance-26.07%-9.32%-6.42%-6.42%1 Month Performance-31.38%-10.26%-0.68%-7.44%1 Year PerformanceN/A-15.08%6.05%-4.31% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$2.58+3.1%N/AN/A$12.38M$662,000.000.00150Gap UpVRPXVirpax Pharmaceuticals1.5161 of 5 stars$1.94-6.3%$3.00+54.6%-98.8%$51.53MN/A0.007Positive NewsGap DownTrading HaltedXFORX4 Pharmaceuticals4.4269 of 5 stars$0.30-4.0%$3.50+1,086.4%-83.5%$51.23M$1.12M-3.2880Analyst RevisionCTORCitius OncologyN/A$0.71+14.5%$3.00+322.5%N/A$50.80MN/A0.00N/AGap DownVNRXVolitionRx1.9228 of 5 stars$0.55-0.4%$3.75+584.3%-30.2%$50.78M$1.29M-1.5280Analyst ForecastGap DownAADIAadi Bioscience0.9509 of 5 stars$2.05+4.6%$1.67-18.7%-22.0%$50.63M$25.07M-0.9040HOWLWerewolf Therapeutics1.8822 of 5 stars$1.12-0.9%$9.00+703.6%-84.9%$50.21M$1.89M-0.7340Gap DownIMMXImmix Biopharma2.4034 of 5 stars$1.82+1.1%$7.00+284.6%-43.9%$50.07MN/A-2.149News CoverageIPSCCentury Therapeutics2.2328 of 5 stars$0.58+5.2%$5.00+756.6%-87.6%$49.63M$6.59M-0.32170Analyst ForecastGap DownITRMIterum Therapeutics1.7443 of 5 stars$1.43-0.7%$5.00+249.7%-23.8%$49.45MN/A-1.0910Positive NewsOTLKOutlook Therapeutics1.0773 of 5 stars$1.50-1.0%$10.20+582.3%-87.1%$48.35MN/A-0.2020Gap Down Remove Ads Related Companies and Tools Related Companies Virpax Pharmaceuticals Alternatives X4 Pharmaceuticals Alternatives Citius Oncology Alternatives VolitionRx Alternatives Aadi Bioscience Alternatives Werewolf Therapeutics Alternatives Immix Biopharma Alternatives Century Therapeutics Alternatives Iterum Therapeutics Alternatives Outlook Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
